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Synaptic failure and neurofibrillary degeneration are two major neuropathological
substrates of cognitive dysfunction in Alzheimer’s disease (AD). Only a few studies
have demonstrated a direct relationship between these two AD hallmarks. To investigate
tau mediated synaptic injury we used rat model of tauopathy that develops extensive
neurofibrillary pathology in the cortex. Using fractionation of cortical synapses, we
identified an increase in endogenous rat tau isoforms in presynaptic compartment,
and their mis-sorting to the postsynaptic density (PSD). Truncated transgenic tau
was distributed in both compartments exhibiting specific phospho-pattern that was
characteristic for each synaptic compartment. In the presynaptic compartment, truncated
tau was associated with impairment of dynamic stability of microtubules which could
be responsible for reduction of synaptic vesicles. In the PSD, truncated tau lowered the
levels of neurofilaments. Truncated tau also significantly decreased the synaptic levels of
Aβ40 but not Aβ42. These data show that truncated tau differentially deregulates synaptic
proteome in pre- and postsynaptic compartments. Importantly, we show that alteration of
Aβ can arise downstream of truncated tau pathology.
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INTRODUCTION
Neurofibrillary tangles, amyloid plaques, neuronal loss and
synaptic failure represent the major hallmarks of Alzheimer’s
disease (AD; Wischik et al., 1988; Rinne et al., 1989; DeKosky
and Scheff, 1990; Cras et al., 1991; West et al., 1994; Coleman
and Yao, 2003). Synaptic deficits occur very early in AD and
correlate well with the severity of dementia in AD patients
(Davies et al., 1987; Masliah et al., 2001; Scheff et al., 2007).
Structural and functional synaptic changes are observed in both
early and late stages of AD (Sze et al., 2000; Masliah et al.,
2001; Honer, 2003; Reddy et al., 2005; Counts et al., 2006).
Moreover, these changes correlate well with the cognitive decline
in AD (DeKosky and Scheff, 1990; Braak and Braak, 1991;
Arriagada et al., 1992; Blennow et al., 1996; Callahan et al.,
2002).
The synaptic damage is characterized by deregulation of
synaptic proteins at the protein and mRNA levels (Coleman
and Yao, 2003; Honer, 2003; Tao et al., 2003). For example,
the level of synaptophysin—a presynaptic vesicle protein—
decreased by 25% in the frontal cortex (Masliah et al., 2001)
and by 35% in the superior temporal and inferior parietal
cortex in AD (Counts et al., 2006). Decrease in synaptogamin
by 52%, and synaptobrevin by 46% in hippocampus and
37% in the occipital cortex have also been demonstrated (Sze
et al., 2000). Moreover, the vesicle protein Rab3a is decreased
by 30% in hippocampus in AD brains (Sze et al., 2000).
Several other proteins such as contactin I and II, SNAP 25,
syntaxin are also deregulated in AD brains (Honer, 2003;
Tannenberg et al., 2006). In addition, the surviving neurons in
AD exhibit decreased levels of mRNA expressing synaptic proteins
(Heffernan et al., 1998; Coleman and Yao, 2003). Loss of synaptic
proteins, therefore, appears to dictate synaptic impairment in
human AD.
Importantly, the pattern of NFT progression parallels synaptic
damage and occurs in the same brain regions (Honer et al.,
1992; Masliah et al., 1992; Wakabayashi et al., 1994; Ingelsson
et al., 2004; Serrano-Pozo et al., 2011). Higher tangle count is
associated with abatement in synaptic proteins in AD brains
(Coleman et al., 1992; Callahan et al., 1994; Callahan and
Coleman, 1995; Honer, 2003). Furthermore, synaptic failure is
also reported in tauopathies such as frontal lobe degeneration
and progressive supranuclear palsy (Brun et al., 1995; Bigio
et al., 2001). Pathological tau then may lead directly to
synaptic pathology in AD and related tauopathies. How the
disease modified tau protein induces synaptic damage, however,
remains unknown. Here we employed rat model of human
tauopathy expressing human truncated tau that recapitulates
AD neurofibrillary degeneration in the isocortex (Filipcik et al.,
2012). Previously, we introduced truncated tau as a driving
force behind neurofibrillary degeneration. Monoclonal antibody
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DC11 that recognized conformationally altered truncated tau
protein (Vechterova et al., 2003) allowed us to identify several
truncated tau species with toxic gain of function. Using
in vitro tau oligomerization assay we selected the most toxic
one that was used as a transgene for generation of rat
models for human tauopathies (Zilka et al., 2006; Koson
et al., 2008; Filipcik et al., 2012). The expression of the
truncated tau in the brain of transgenic animals induced the
complete tau cascade of neurofibrillary degeneration as found
in humans. Truncated tau induced tau hyperphosphorylation,
formation of Gallyas-positive intracellular and extracellular
tangles also exhibiting Congo Red birefringence and thioflavin
S reactivity, formation of sarkosyl-insoluble misfolded tau
complexes containing both truncated and endogenous rat tau
(Zilka et al., 2006; Filipcik et al., 2012). In this study, we
demonstrate that truncated tau selectively alters synaptic tau,
amyloid and cytoskeletal proteins in the pre- and postsynaptic
compartments. Our findings suggest that truncated tau is a
potent inducer of synaptic damage synapses independent of Aβ
pathology.
MATERIALS AND METHODS
TRANSGENIC RATS
Heterozygous transgenic male rats expressing human N- and C-
terminally truncated tau encompassing three repeats (aa 151–391;
line SHR24; Filipcik et al., 2012) and age matched wild type rats
were used in this study. Rats were housed in cages with adequate
supply of water, and 12 h day/light cycle. Animals in the age of
14–16 months were sacrificed by cervical dislocation and brains
were isolated and frozen. For each experiment, four animals per
group were used; three animals were used for electron microscopy
(EM). Left cortex was used for synaptosomal fractionation and
right cortex was used for isolation of sarkosyl insoluble tau.
All experiments were performed in accordance to the Slovak
and European Community Guidelines, with the approval of
the Ethical Committee of Institute of Neuroimmunology and
the State Veterinary and Food Administration of the Slovak
Republic.
ANTIBODIES
Primary antibodies used in this study and corresponding
dilutions are provided in Table 1. Antibodies were diluted in
fat free milk or BSA in 1 × Tris buffered saline with tween
20 or according to instructions provided by the manufacturer.
Secondary antibodies were purchased from DAKO (DAKO,
Glostrup, Denmark).
SYNAPTOSOMAL FRACTIONATION
Synaptosomal fractionation was performed according to
previously published protocols (Hahn et al., 2009; Ciani
et al., 2011) with minor modifications. Briefly, tissues were
homogenized in Buffer A containing 0.32 M sucrose, 4 mM
HEPES at pH 7.4 and protease inhibitor cocktail. Cell debris
and nuclei were removed by centrifugation at 800 × g for 10
min and the resulting supernatant was collected (labeled S1). A
fraction of S1 was stored and used as total protein extract. The
pellet was re-suspended in buffer A and centrifuged at 800 × g
for 10 min, the resulting supernatant and S1 were pooled and
spun at 9000 × g for 15 min producing supernatant (S2) and
pellet (P2). The pellet P2 was further suspended in buffer A and
layered over a discontinuous sucrose gradient (0.8/1.0/1.2 M
sucrose in 4 mM HEPES, pH 7.4) and spun at 65,000 × g for
45 min in MLS 50 rotor, Beckmann ultracentrifuge (Beckmann
instrument Inc, California, US). The synaptosomal fraction
at interface 1.0 M and 1.2 M sucrose was carefully collected
and suspended in buffer B containing 0.32 M sucrose, 4 mM
HEPES and 150 mM NaCl with phosphatase and protease
inhibitors. The synaptosomal fractions were then incubated
on ice in an equal volume of buffer C containing 1% Triton
X-100, 0.32 M sucrose and 12 mM Tris at pH 8.0 for 15 min.
After 15 min, the samples were centrifuged at 82,500 × g for
45 min. The triton extractable fractions (supernatant) represent
the presynaptic fraction (synaptic membrane fraction (SMF))
containing the presynaptic proteins and the pellet correspond
to postsynaptic density (PSD). All steps were performed in
4◦C and aliquots of samples were stored in –80◦C. Protein
concentration was determined using BCA assay (Bio-rad
laboratories Inc, California, USA) and equal amounts of proteins
were loaded onto sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (PAGE) gels. Anti-synaptophysin and
anti-PSD95 antibodies were used to assess the purity of the
fractions.
SARKOSYL FRACTIONATION
Sarkosyl insoluble tau was extracted according to published
protocols (Greenberg and Davies, 1990; Zilka et al., 2006).
Right cortex of wild-type (wt) and transgenic animals were
homogenized using OMNI homogenizer in buffer containing
20 mM Tris pH 7.4, 800 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 10% sucrose and protease inhibitors. After centrifugation
at 20,000 × g for 20 min the supernatant (S1) was collected
and small fraction was saved as total protein extract. Sarkosyl
(40% w/v in water) was added to the final concentration of
1% and mixed by stirring for 1 h at room temperature. The
samples were then centrifuged at 100,000 × g for 1 h at
25◦C using Beckmann TLA 100 (Beckmann instrument Inc,
California, USA). Pellets were washed in PBS and finally dissolved
in SDS loading buffer to 1/50 volume of S1 and 20 µg
w/v corresponding to S1 fraction was used for western blot
analysis.
WESTERN BLOTTING
Proteins were resolved on 12% SDS-PAGE and transferred
to nitrocellulose membrane. The membranes were incubated
in 5% non-fat free milk or BSA in 1 × TBS-Tween for
1 h. The blots were incubated with primary antibodies for
2 h at room temperature or overnight at 4◦C. Blots were
developed using enhanced chemiluminiscence western blotting
detection system SuperSignal West Pico chemiluminescenscent
Substrate (Thermo Scientific, USA) on Image Reader LAS-
3000 (FUJI Photo Film Co, Ltd, Tokyo, Japan). Modified
tubulin blots were stripped and re-probed using total α-
tubulin antibody for quantitation. Actin was used as loading
control and all relevant data were normalized to actin.
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Table 1 | List of primary antibodies, clonality, and dilution used.
Antibody (clone) Clonality Dilution Source
Anti-tau DC25 Mouse monoclonal 1:1∗ Axon Neuroscience (Bratislava, Slovak Republic)
Polyclonal anti-tau antibody Rabbit polyclonal 1:5000 Axon Neuroscience (Bratislava, Slovak Republic)
Anti-β-tubulin (DC126) Mouse monoclonal 1:1∗ Axon Neuroscience (Bratislava, Slovak Republic)
Anti-tyrosinated tubulin Rat monoclonal 1:1∗ Axon Neuroscience (Bratislava, Slovak Republic)
Anti-DC39C Mouse monoclonal 1:1∗ Axon Neuroscience (Bratislava, Slovak Republic)
Anti-synaptophysin Mouse monoclonal 1:3000 Synaptic Systems (Gottingen, Germany)
Anti-α-tubulin Mouse monoclonal 1:2500 Synaptic Systems (Gottingen, Germany)
Anti-neuroligin Mouse monoclonal 1:2000 Synaptic Systems (Gottingen, Germany)
Anti-drebrin Rabbit polyclonal 1:2000 Abcam (Cambridge,UK)
Anti-acetylated–tubulin (6–11B–1) Mouse monoclonal 1:3000 Abcam (Cambridge,UK)
Anti-bassoon (SAP7F407) Mouse monoclonal 1:1000 Abcam (Cambridge,UK)
Anti-actin (ACTN05) Mouse monoclonal 1:2500 Abcam (Cambridge,UK)
Anti-neurofilament antibody (SMI 312) Mouse monoclonal 1:1000 Abcam (Cambridge,UK)
Amyloid precursor protein (22C11) Mouse monoclonal 1:1000 Millipore (California, USA)
Anti-tubulin detyrosinated Rabbit polyclonal 1:2000 Millipore (California, USA)
Anti-PSD95 (7E3–1B8) Mouse monoclonal 1:2500 Thermo–scientific (Illinois USA)
Anti-GAP43 Mouse monoclonal 1:2500 Novus biological (Cambridge,UK)
Anti-MAP 2 (2a+2b) Mouse monoclonal 1:2500 Sigma (Vienna,Austria)
Anti-tau pT205 Rabbit polyclonal 1:1000 Invitrogen (California, USA)
Anti-tau pT212 Rabbit polyclonal 1:1000 Invitrogen (California, USA)
Anti-tau pS214 Rabbit polyclonal 1:1000 Invitrogen (California, USA)
Anti-tau pS262 Rabbit polyclonal 1:1000 Invitrogen (California, USA)
Anti-tau pS356 Rabbit polyclonal 1:500 Abcam (Cambridge,UK)
Anti-tau DC11 Mouse monoclonal 1:100 Axon Neuroscience (Bratislava, Slovak Republic)
Anti-actin Mouse monoclonal 1:2500 Abcam (Cambridge,UK)
∗ Supernatant from cultured hybridoma cells was used.
The western blots (WB) were quantified using Advanced
Image Data Analyzer software (AIDA Biopackage Raytest,
Germany).
QUANTIFICATION OF AMYLOID β USING ELISA
Total synaptosomes were extracted as described earlier and used
to quantify amyloid-β40 (Aβ40) and β42. Protein concentration
was determined using BCA protein estimation and 400 µg of
total synaptosomes were used for assay. Eight samples per group
were analyzed. Amyloid β assay kits (WAKO, Japan) were used for
assay and experiments in duplicates were performed according to
manufacturer’s instructions.
CONFOCAL MICROSCOPY
Rats were perfused with phosphate saline buffer (PBS, pH
7.2) followed by 4% paraformaldehyde (PFA, pH 7.2), and
the brains were removed. Tissues were postfixed in 4%
PFA overnight, followed by treatment with 25% sucrose for
48 h to provide cryoprotection. Brains were then frozen in
isopentane at −40◦C. Coronal sections (40 µm) were cut
in a cryostat at −18◦C. Free-floating sections were incubated
with primary antibodies (rabbit polyclonal anti-P-tau T205,
mouse monoclonal DC11) overnight at 4◦C. Sections were
subsequently incubated with secondary antibodies conjugated
with ALEXA 488 or ALEXA 546 fluorescent dyes (Invitrogen-
Molecular Probes, Eugene, OR, USA) for 1 h at room
temperature. After washing, the sections were mounted onto
slides using Vectashield mounting medium (Vector Laboratories),
and examined with an Olympus IX 71 Fluorview laser scanning
confocal microscope.
ELECTRON MICROSCOPY
Rats (n = 3) were perfused with 300 mmol/l glutaraldehyde in
100 mmol/l cacodylate buffer, their brains were extracted and
fixed in the same buffer overnight. Brains were cut to pieces
(1 mm3), and postfixed in 40 mmol/l osmium tetroxide in
100 mmol/l cacodylate buffer (1 h). After rinsing in cacodylate
buffer and dehydration in ethanol, samples were embedded
in araldite resin (Durcupan ACM, Fluka). Ultrathin sections
(60 nm thick) were cut using Leica EM UC6 ultramicrotome
and stained with uranylacetate and lead citrate. Sections were
examined under FEI Morgagni 268D electron microscope (FEI
Company, Prague, Czech Republic) at 70 kV. Comparative images
were captured using the same resolution as indicated in the EM
micrographs.
DATA ANALYSIS
All experiments were repeated three times for consistency.
Only one randomly selected value per experiment, however,
was used for statistical analysis. Representative blots are
shown. Statistical analyses were performed with R software
(R Development Core Team, 2014). To avoid the pure
asymptotic behavior of commonly used statistical methods,
such as Student’s t-test or ANOVA, in our experimental
design, we evaluated the differences between the means
using a nonparametric bootstrap-t method (1000 bootstrap
replications of the data) on the significance level α =
0.05. Bootstrap two-sample t-statistics were used as the test
criterion. Additionally, we calculated the 95% bootstrap-
t empirical confidence intervals (CI; Efron and Tibshirani,
1993) for the differences between the means. Statistical
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 24 | 3
Jadhav et al. Truncated tau deregulates synaptic proteome
results are presented as bootstrap p-values, Monte-Carlo (MC)
estimates of the mean differences, and MC estimates of
upper and lower bounds of 95% CI. The statistical results
are expressed by p-values, mean differences, and CI in the
form “(lower bound, upper bound)”. If the p-value is greater
or equal than 0.05, the CI includes zero; if the p-value is
smaller than 0.05, the CI does not include zero. Graphs
representing data points and mean for individual protein per
group were generated using PRISM (GraphPad Software, Inc.
California, USA), where ∗p ∈ 〈0.01, 0.05); ∗∗p ∈ 〈0.001,
0.01); ∗∗∗p ∈ (0, 0.001) are used to indicate statistical
significance.
RESULTS
CORTICAL TAU NEUROFIBRILLARY PATHOLOGY IS A HALLMARK OF THE
TRANSGENIC RAT MODEL OF HUMAN TAUOPATHY
Sarkosyl insoluble tau is considered the proteomic correlate
of the mature neurofibrillary degeneration. We isolated both
soluble and sarkosyl insoluble tau from the cortices of wild-
type and transgenic animals. Using pan tau antibody DC25,
we observed an identical pattern of endogenous rat tau
in soluble fractions, and an additional presence of human
truncated tau in the transgenic animals (Figure 1A). In the
sarkosyl insoluble tau fractions isolated from transgenic
rats, tau assembly comprised of higher and low molecular
weight tau species. In the wild-type rat brain extracts
sarkosyl insoluble tau was absent (Figure 1B). Transgenic rats
developed extensive neurofibrillary degeneration in the cortex.
Neurofibrillary pathology was composed of both phosphorylated
(Figure 1C) and truncated tau species (Figure 1D). Confocal
micrographs revealed that the majority of neurons contained tau
phosphorylated at threonine 205 and DC11 positive truncated
tau (Figure 1E).
TRUNCATED TAU IMPAIRED SYNAPTIC TAU PROTEOME IN THE RAT
MODEL OF TAUOPATHY
To investigate synaptic damage induced and driven by truncated
tau we assessed the distribution of rat endogenous tau and
human truncated tau in the synaptic membrane fraction (SMF)
and postsynaptic density fraction (PSD). In SMF, pan tau
antibody DC25 recognized endogenous rat tau in both wild-type
and transgenic animals (Figure 2A). Postsynaptically, however,
endogenous tau was present almost exclusively in PSD of
transgenic rats, and only traces were observed in the PSD
of wild-type animals (Figure 2B). We further confirmed the
presence of endogenous tau in the postsynaptic fraction in
transgenic rats using DC39C antibody that specifically recognizes
the C-terminus of tau protein and thus stains only endogenous
rat tau (Figure 2C). Human truncated tau was distributed in
both synaptic fractions in transgenic animals (Figures 2A,B).
Quantifying the levels of endogenous tau revealed a significant
increase in rat tau isoforms in the pre-synaptic (p = 0.003; 215.38;
(158.20, 272.56), Figure 2D) and post-synaptic compartments
(p = 0.002; 150.79; (125.06, 176.52), Figure 2D) in transgenic
rats.
We evaluated the purity of synaptic fractions using either
synaptophysin—a specific marker for presynaptic compartment,
or PSD95—a specific marker for the PSD (Figure 2E). Blots
were probed with synaptophysin and then re-probed with PSD95.
There was very little or no cross-contamination between the
synaptic fractions.
SYNAPTIC TRUNCATED TAU EXHIBITED DIFFERENT
PHOSPHORYLATION PATTERNS IN PRE- AND POSTSYNAPTIC
COMPARTMENTS OF TRANSGENIC ANIMALS
Phosphorylation regulates microtubule binding activity of the
tau protein. In AD brains, site specific phosphorylation of
tau correlates with neuronal pathology (Augustinack et al.,
2002). Therefore, we evaluated tau phospho-pattern in the
synaptic compartments of transgenic animals. We focused on
phospho tau epitopes that play important role in AD namely—
T205, T212, S214, S262, and S356. We selected antibodies
specifically recognizing these tau phospho-sites and investigated
the phospho-status of truncated tau in the presynaptic fraction
(SMF) and PSD fraction of transgenic rats (Figures 3A–D). The
blots were stained with respective phospho-antibodies, stripped
and re-stained using polyclonal anti-tau antibody (poly-tau).
Phospho-tau levels were normalized to total tau levels.
Densitometric analysis revealed significant differences in
tau phospho-pattern in the synaptic fractions (Figure 3E).
Interestingly, antibodies recognizing phosphorylation at T205,
S214, S262 and S356 displayed higher immunoreactivity in the
presynaptic fraction (pT205, p = 0.006; –0.16; (–0.218, –0.095);
pS214, p = 0.003; –0.28; (–0.304, –0.258); pS262, p = 0.009; –
0.27; (–0.325, –0.221); pS356, p = 0.006; –0.39; (–0.545, –0.239)),
while antibody specific for phospho-T212 showed increased
immunoreactivity in the PSD when compared to SMF (p = 0.008;
0.23; (0.163, 0.305)) (Figure 3F).
TRUNCATED TAU SELECTIVELY DAMAGED CYTOSKELETAL PROTEINS
IN PRE- AND POSTSYNAPTIC COMPARTMENTS OF TRANSGENIC RATS
Tau is a major microtubule binding protein localized mainly in the
axons, and plays an important role in microtubule polymerization
and stability. Therefore we investigated the pathological effect
of truncated tau presence on cytoskeletal proteins in the
presynaptic compartments. Strikingly, we observed a significant
increase in levels of total α-tubulin (p = 0.002; 154.97; (100.71,
209.23)) and a sizeable increase in levels of total β-tubulin
(p = 0.048; 139.15; (14.17, 264.12)) in the SMF fractions
of transgenic animals when compared with wild-type rats
(Figures 4A,C).
We next investigated whether the specific increase of
tubulin might affect the dynamic instability of microtubules in
the presynaptic compartment in transgenic rats. Microtubule
polymerization is associated with several posttranslational
modifications of tubulin and specific modifications influence
the microtubule stability in vivo (Verhey and Gaertig, 2007). To
investigate posttranslational modifications of synaptic tubulin,
we used antibodies specific to tyrosinated tubulin—a marker
for unstable microtubules (Paturle et al., 1989; Marcos et al.,
2009), and detyrosinated and acetylated tubulin—markers for
stable microtubules (Webster et al., 1987; Hammond et al.,
2008; Figures 4A,C). We found a significant increase in
detyrosinated (p = 0.006; 65.06; (40.76, 89.37)) and acetylated
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FIGURE 1 | Neurofibrillary degeneration in the cortex of
transgenic rat model for human tauopathy. (A) Western blots
(WB), using pan-tau antibody DC25, showed no change in the
expression of total endogenous rat tau in the cortex of transgenic
rats (Tg) when compared to wild-type rats. Expression of
transgenic human truncated tau (151–391) was similar in all tested
transgenic animals. Actin was used as loading control.
(B) Antibody DC25 recognizes extensive sarkosyl insoluble tau in
the cortex of transgenic rats. No sarkosyl insoluble tau was
observed in control animals. Recombinant tau isoforms (6i) and
human truncated tau 3R (151–391) were used as controls.
(C) Confocal microscopy revealed many neurofibrillary tangles
containing phosphorylated tau at T205. (D) Many neurofibrillary
tangles contained DC11 positive truncated tau. (E) Colocalization of
pT205 and DC11 positive tangles (merged C and D). Scale bar =
100 µm.
tubulin (p = 0.015; 166.63; (64.77, 268.48)) in the presynaptic
compartments of the transgenic rats compared to wild-type rats.
However, we observed no significant change in the levels of
tyrosinated tubulin when compared to wild-type rats (p = 0.209;
70.49; (–103.20, 244.18)).
In the PSD, truncated tau-induced cytoskeletal changes
were different than in the SMF. We detected no significant
changes in the levels of total α-tubulin or total β-tubulin in
the PSD (Figures 4B,D; total α-tubulin p = 0.224; 144.46;
(–85.59, 374.52); total β-tubulin p = 0.902; –12.71; (–145.13,
119.70)). In addition, we did not observe any change in acetylated
tubulin levels in the PSD (data not shown). Furthermore, the
levels of MAP2—a dendrite specific microtubule binding
protein also remained unaltered. However, we found
significant changes in neurofilament proteins (Figures 4B,D).
Neurofilaments represent a major component of the PSD,
and are localized in close proximity to the PSD membrane
(Blomberg et al., 1977; Liu et al., 2006). We observed a
significant decrease in neurofilament H (p = 0.017; –181.91;
(–281.23, –82.59)) and neurofilament M (p = 0.006; –141.06;
(–196.73, –85.39)). Additionally, we also observed a slight
nonsignificant decrease in drebrin E/A (p = 0.578; 79.85;
(–73.75, 233.45)), a dendrite-specific actin-binding protein,
that regulates spine morphology and size levels (Ivanov et al.,
2009).
TRUNCATED TAU DEREGULATED SYNAPTIC MARKERS ONLY IN
PRESYNAPTIC COMPARTMENTS IN TRANSGENIC RATS
Several presynaptic and postsynaptic proteins are deregulated
in human AD and other tauopathies. To study the effect
of truncated tau presence on synaptic markers, we assessed
the levels of selected presynaptic and postsynaptic proteins
in synaptic fractions (Figures 5A,C). Western blotting
analysis revealed significant decrease in synaptophysin
levels in the presynaptic fraction of transgenic rats in
comparison to wild-type animals (p = 0.026; –211.81;
(–328.96, –94.65)). In contrast to synaptophysin, we observed
only nonsignificant increase in bassoon—a synaptic vesicle
clustering protein (p = 0.056; 137.73; (−25.38, 300.86)),
and no change in the levels of GAP 43 protein, a neurite
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FIGURE 2 | Tau proteome was elevated and mislocalized in
synapses of transgenic rats. (A) WB analysis of presynaptic fractions
using DC25 antibody revealed the presence of endogenous tau and
truncated tau in the presynaptic compartments of wild-type and
transgenic animals. Endogenous tau levels were, however, elevated in
the presynaptic compartments of transgenic rats compared to wild-type
rats. (B) WB analysis of PSD using DC25 antibody in wild-type and
transgenic rats showed the presence of truncated tau in the PSD of
transgenic rats. Very faint, if any, endogenous tau was observed in
PSD of wild-type animals. Recombinant tau isoforms (6i) and truncated
tau (3R) were used as controls in both (A) and (B). (C) WB using
DC39C—an antibody recognizing exclusively full length tau
isoforms—confirmed the presence of endogenous rat tau in the post
synaptic density of the transgenic rat cortex. Faint staining of tau was
present in the PSD of wild-type rats. Recombinant tau isoforms (6i)
were used as control. (D) Endogenous tau increased significantly in
presynaptic as well as postsynaptic fraction. Graphs show individual
data points and means for tau protein levels for each group in
individual compartments. Statistical evaluation revealed changes in
endogenous tau protein levels in the pre and postsynaptic fractions.
Data represents three individual experiments (***p ∈ (0, 0.001)).
(E) Isolated presynaptic and postsynaptic fractions were immunostained
using anti-synaptophysin and anti-PSD95 antibodies for assessment of
the purity of synaptic fractions. Pure synaptic fractions were observed
in both wild-type and transgenic animals. Actin was used as loading
control.
growth cone protein (p = 0.278; 81.67; (−24.36, 187.71)).
In the PSD, we did not detect any significant changes in
the levels of PSD95 and neuroligin, a ligand for presynaptic
β-neurexins (Figures 5B,D; PSD95: p = 0.284; –51.80; (–
161.13, 57.53), Neuroligin: p = 0.197; 111.42; (–43.03, 265.88))
(Figures 8A,B).
TRUNCATED TAU REDUCED NUMBER OF SYNAPTIC VESICLES AND
INDUCED FORMATION OF MICROTUBULAR BUNDLES
To investigate the ultrastructural changes in the synapses of
transgenic animals in vivo, we examined cortical sections of
wild-type and transgenic animals using electron microscopy
(EM). EM micrographs revealed a decrease in synaptic vesicles
in the synapses of transgenic animals (Figures 6A,B). To
further characterize the changes in synaptic vesicles, we
counted the number of synaptic vesicles per synapse in
randomly selected sections in the wild-type and transgenic
animals. Synaptic vesicles from 60 synapses/animal exhibiting
preserved junctions were counted in wild-type (n = 3) and
transgenic animals (n = 3) by a blind observer. The number
of vesicles per synapse decreased significantly in transgenic
rats compared to wild type rats (Figure 6C; p < 0.0001; –44.05;
(–53.27, –34.82)), corresponding to the decrease in synaptophysin
levels (Figure 5C). Consistent with the results obtained
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FIGURE 3 | Phosphorylation pattern of tau proteome was different in
presynaptic and postsynaptic compartments of transgenic animals.
Immunoblots of presynaptic and postsynaptic fractions from transgenic
animals using antibodies against phosphorylated tau at (A) threonine 205
(pT205), (B) threonine 212 (pT212), (C) serine 214 (S214), (D) serine 262
(S262), (E) serine 356 (S356). For relative quantification, each blot was
stripped and reprobed with polyclonal anti-tau (total tau). (F) Blots revealed
increased phosphorylation of tau at residues T205, S214, S262, and S356 in
the presynaptic compartments, and increased phosphorylation at T212 in the
postsynaptic fraction. Graph showing data points and means for specific
tau-phospho epitopes in individual groups. Statistical evaluation revealed
differences in phospho-tau levels from WB (***p ∈ (0, 0.001)).
from synaptic fractionation, we observed microtubule
bundles in the presynaptic terminals of transgenic animals
(Figure 6D).
TRUNCATED TAU-MEDIATED DEREGULATION IS NOT DEPENDENT
ON Aβ
To identify the position of amyloid cascade in truncated tau-
mediated synaptic deficits, we compared the levels of APP,
amyloid-β 42 (Aβ42) and Aβ40 in synapses of transgenic
and wild-type animals. Staining using anti APP antibody
(clone 22C11) revealed no change in the levels of total
APP in the transgenic animals (Figures 7A,B; p = 0.868;
–84.30; (–419.99, 251.39)). Furthermore, we quantified
the levels of amyloid peptides Aβ40 and Aβ42 in total
synaptosomes by quantitative ELISA. The quantification
did not reveal any changes in the levels of toxic Aβ42 in
transgenic animals when compared to wild-type rats (Figure 7C;
p = 0.878; 0.01; (–0.22, 0.24)). The levels of Aβ40 were,
however, significantly reduced (p = 0.022; –2.86 ; (–5.07,
–0.64)) in synapses of transgenic animals.
THE LEVELS OF SYNAPTOPHYSIN AND TUBULIN IN TOTAL BRAIN
EXTRACTS SHOWED NO CHANGES IN TRANSGENIC ANIMALS WHEN
COMPARED TO CONTROLS
To verify that the observed differences were specific for synapses,
we also quantified the levels of selected proteins in total brain
extracts (Figures 8A,B). Immuno-quantification of total protein
extract revealed no changes in the levels of synaptophysin
(p = 0.633; –3.31; (–48.64, 42.01)), α- tubulin (p = 0.822;
24.82; (–175.76, 225.41)) and β-tubulin (p = 0.376; –22.22;
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 24 | 7
Jadhav et al. Truncated tau deregulates synaptic proteome
FIGURE 4 | Effect of truncated tau on cytoskeletal proteins in presynaptic
and postsynaptic compartments of transgenic rats. (A) The levels of
acetylated and detyrosinated tubulin increased selectively in the presynaptic
fraction. WB of presynaptic fractions from wild-type (wt) and transgenic (tg)
rats with specific tubulin antibodies as indicated. Modified tubulin levels were
normalized to total tubulin levels. Actin was used as loading control.
(B) Presynaptic levels of α-tubulin and β-tubulin along with acetylated-tubulin
and detyrosinated tubulin increased, whereas levels of tyrosinated tubulin did
not change. (C) Levels of neurofilament proteins decreased in PSD of
transgenic rats. WB comparing cytoskeletal proteins of postsynaptic densities
of wild-type (wt) and transgenic (tg) rats. Actin was used as loading control.
(D) Postsynaptic levels of total tubulin protein levels (α/β) did not change,
whereas levels of neurofilaments H and M decreased in transgenic rats when
compared to wild-type rats. Significant decrease in levels of neurofilament H
and neurofilament M in the postsynaptic densities of transgenic rat compared
to wild-type. In both (B) and D), graphs show data points and the mean
values for individual pre- or postsynaptic cytoskeletal proteins per group (**p
∈ 〈0.001, 0.01); ***p ∈ (0, 0.001)).
(–55.21, 10.76)) suggesting that the pathological changes were
present exclusively in the synaptic terminals of the transgenic
animals.
DISCUSSION
Synaptic failure and neurofibrillary tangles strongly correlate with
cognitive decline in AD (Terry et al., 1991; Samuel et al., 1994).
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FIGURE 5 | Truncated tau deregulated selected synaptic proteins in rat
model. (A) Immunoblots of presynaptic fractions with antibodies against
synaptophysin, Bassoon and GAP 43. Actin was used as loading control.
(B) Graphs show data points and the mean values for the presynaptic
proteins per group. Statistical evaluation of presynaptic proteins revealed
decrease in synaptophysin levels (*p < 0.05), no change in bassoon levels,
and no change in GAP 43 protein levels. (C) Western blots of postsynaptic
fraction with PSD95 and neuroligin indicated no change in the levels of these
proteins when compared to wild-type rats. (D) Graphs show data points and
mean values of postsynaptic proteins for individual groups. Statistical
evaluation of postsynaptic proteins revealed no significant change in PSD 95
and neuroligin levels.
Growing body of research has demonstrated that AD brains show
a marked reduction in synaptic density and a loss of dendritic
spines in cortex and hippocampus (DeKosky and Scheff, 1990).
The loss of synaptic proteins and the reduction of dendritic
processes in AD were also attributed to tau neurofibrillary
pathology (Callahan and Coleman, 1995; Falke et al., 2003;
Ramsden et al., 2005; Kambe et al., 2011). Several recent reports
have demonstrated that microtubule associated protein tau
induced synaptic impairment. This process is mainly regulated by
N-methyl-D-aspartate receptor-dependent tau phosphorylation
(Ittner et al., 2010; Mondragón-Rodríguez et al., 2012). However,
these studies focused mainly on the post-synaptic compartment
and the toxic effects of misfolded tau on the pre-synaptic
compartment are poorly understood. Furthermore, data on the
pathological tau proteome in the synaptic compartments are
missing.
To unravel the pathological signature of truncated tau in
both synaptic compartments we utilized rat model for human
tauopathy, expressing truncated tau in the central nervous system.
The rats express express six tau isoforms in the brain, similar to
humans (Hanes et al., 2009), and represent an excellent model
for human AD. Moreover, the rat model develops an extensive
neurofibrillary degeneration in the cortex that fulfills the criteria
for human AD neurodegeneration, including argyrophilia,
thioflavin S positivity and Congo red birefringence (Filipcik
et al., 2012). The synaptic biology, signaling and proteome have
also been extensively studied in these rats, which enabled us
to study the pathological changes of synaptic structure in a
well characterized animal model. Furthermore, we used a well-
established synaptic fractionation protocol that has been applied
extensively to investigate the biology and proteome of synaptic
fractions (Cohen et al., 1977; Rebola et al., 2003; Zhou et al., 2007;
Ciani et al., 2011; Rodrigues et al., 2014; Sahara et al., 2014) and
to examine post-mortem human brains from AD (Tai et al., 2012)
and other neuropsychiatric diseases (Hahn et al., 2009).
Here we demonstrated that rat tau proteins were distributed
differentially in synaptic compartments in transgenic and age-
matched control rats. Specifically, in control rats, the amount
of the endogenous rat tau in post-synaptic compartment was
significantly lower than in pre-synaptic compartment. These
results are consistent with a recent study showing synaptic
localization of tau in human brains (Tai et al., 2012) and
corroborate the similarity between rat and human synaptic tau
proteome. In transgenic rat brains, we observed a significant
increase in tau protein in the post-synaptic density when
compared to age-matched controls. Similarly, increase in tau
protein along with tau aggregation was detected in the PSD of
AD brain (Fein et al., 2008; Tai et al., 2012). This suggests that the
normal sorting mechanism of tau protein is compromised in the
transgenic animals, similar to AD brains. These results also show
that tau mis-sorting may represent a key step in the tau mediated
neurodegeneration.
Synaptic tau proteome in transgenic animals exhibited
different phosphorylation patterns in the pre- and postsynaptic
compartments. In transgenic animals, truncated tau in the
presynaptic compartment was heavily phosphorylated in the
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FIGURE 6 | Number of synaptic vesicles was reduced in synapses of
transgenic animals. Representative electron micrographs of synapses from
(A) wild-type (wt), and (B) transgenic (tg) rats. (A) Synapses in wild-type rats
showed an intact synaptic junction and presence of numerous synaptic
vesicles. (B) Electron micrographs of synapses from transgenic rats revealed
a decrease in the number of synaptic vesicles. (C) The number of synaptic
vesicles decreased significantly in transgenic animals. Graph shows the
difference between synaptic vesicle count/synapse in wild-type and
transgenic animals (***p ∈ 〈0.001, 0.01)). (D) Electron micrographs from
transgenic animals revealed the presence of microtubule bundles (arrows) in
presynaptic terminal of transgenic animals. The asterisk indicates the
postsynaptic terminal. Scale bars for micrographs = 500 nm.
microtubule binding domain and the proline rich region in
comparison to the PSD. An identical pattern has been suggested
by several studies indicating that pathological phosphorylation
of tau begins in the axons (Papasozomenos and Su, 1991;
Khatoon et al., 1994; Andorfer et al., 2003). Our results further
show that tau hyperphosphorylation displays distinct pattern
in the pre- and postsynaptic compartments, which suggest
that different phospho-tau species are distributed in SMF and
PSD.
The difference in the composition of truncated tau proteome
in synaptic compartments may be responsible for the pattern
of damage in the pre- and postsynaptic compartments. In
presynaptic terminals, truncated tau species impaired dynamic
microtubular instability leading to formation of microtubule
bundles. These results are consistent with our previous findings,
in which we demonstrated the formation of abnormally thick
microtubules in vitro, after incubation of tubulin with truncated
tau (Zilka et al., 2006). Furthermore, the expression of tau
protein resulted in increased tubulin acetylation (Takemura et al.,
1992; Perez et al., 2009), which could be one of the factors
leading to microtubule bundling in the presynaptic terminals.
In addition, several unknown factors may contribute to tau-
induced microtubule bundling in vivo (Lee and Rook, 1992).
Interestingly, a fraction of truncated tau in the presynaptic
compartment was phosphorylated at T205, S214, pS262,
and S356. Since phosphorylation at these residues detaches
tau from microtubules (Fischer et al., 2009) the specific
enrichment of these phospho-tau residues in the presynaptic
terminals may prevent tau from binding to microtubules,
possibly indicating a compensatory mechanism to minimize
microtubule bundling. Highly stable microtubules, however,
may impair the mobility of synaptic vesicles. Indeed, here
we documented a significant decrease in the number of
vesicles in the presynaptic terminals of transgenic rats when
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FIGURE 7 | Amyloid-β 40 was reduced in the synapses of transgenic
animals but not amyloid-β 42. (A) Immunoblot using N- terminal antibody
of APP showed no change in the levels of APP in transgenic rats (tg) with
respect to wild-type (wt) rats. Actin was used as loading control. (B) Levels
of amyloid precursor protein did not change. (C) Graphs show data points
and means of individual groups for the Aβ42 and Aβ40 peptides. Levels of
amyloid-β alloforms in total synaptosomes showed no change in Aβ42 and a
significant decrease in Aβ40 (*p ∈ 〈0.01, 0.05)).
compared to controls. This reduction was also reflected by
decrease in the levels of synaptophysin, a membrane protein
of synaptic vesicles. Decrease in the number of vesicles in
the synaptic terminals of transgenic animals may lead to
decreased neurotransmitter release and in turn affect inter-
neuronal synaptic dialog. However, the total synaptophysin
and tubulin levels remained unchanged suggesting that the
deregulation in these proteins occurs mainly in the presynaptic
terminals.
In contrast to presynaptic terminals, truncated tau did not
affect microtubule stability in the postsynaptic terminals. This
difference may be attributed to the regional binding affinity of tau
and the preference to axonal tubulin binding activity in neurons
(Kanai and Hirokawa, 1995). Although microtubules were
unaffected, the levels of cytoskeletal proteins, neurofilaments
FIGURE 8 | Total protein levels of synaptophysin and tubulins were
unaltered. (A) Immuno blots of total protein extracts from wild-type (wt)
and transgenic animals (tg) against total synaptophysin, total α-tubulin, total
β-tubulin proteins. Actin was used as loading control. (B) Graph shows data
points and mean for tubulin proteins and synaptophysin in each group. No
significant changes in the protein levels were observed.
H and M, were significantly altered in the PSD. Decrease in
neurofilaments has been reported in the early and late stages of
AD (Kittur et al., 1994; Bajo et al., 2001; Counts et al., 2006).
Neurofilaments regulate transport of cytoskeletal components,
are tightly linked to the dendritic arborization in adult neurons,
and play a crucial role in dendritic spine morphogenesis (Willard
and Simon, 1983). Therefore, impaired structural assembly of
neurofilaments may also alter excitatory and inhibitory synaptic
activity.
Mocanu et al. (2008) showed that expression of truncated
tau fragment K18 containing mutation ∆K280 in the pro-
aggregation mice led to the reduction of dendritic spines and
downregulation of synaptophysin in the hippocampal area CA1–
CA3. The K18 tau fragment (Gln244-Glu372) is involved in
the tau fragment used in this study (Ile151-Glu391). Both
fragments contained structural determinants on mis-disordered
tau protein that are essential for pathological tau–tau interaction
(Kontsekova et al., 2014). However, it is important to note, that
there is no tau mutation in AD and therefore our transgenic
rat model expressing truncated tau with no tau mutation
may better reflect tau pathological modification relevant for
AD.
In order to delineate the role of amyloid-β in synaptic
failure driven by truncated tau, we quantified the amounts
of the most abundant amyloid beta alloforms Aβ42 and
Aβ40 in synaptosomes. In human brain, the peptides co-
exist under normal physiological conditions in an Aβ42:Aβ40
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ratio of ∼1:9 (Pauwels et al., 2012). We observed a similar
ratio in our control rats. However, in transgenic rats this
ratio was altered due to the decrease in Aβ40 levels and no
detectable changes in the levels of Aβ42. It has been shown
that Aβ40 is less neurotoxic than Aβ42 (Jan et al., 2008). The
amyloidogenic activity of Aβ42 is 10-fold higher than that of
Aβ40 (Matsuzaki, 2011) and their modes of oligomerization
are distinct (Bitan et al., 2003). Furthermore, oligomeric Aβ40
did not induce inhibition of synaptic transmission unlike
oligomeric Aβ42 (Moreno et al., 2009). Here we showed
that the levels of Aβ42 were unaltered in the cortex of
transgenic animals, demonstrating that the pathological changes
associated with truncated tau are independent from Aβ42 toxicity.
On the other hand, the truncated tau protein significantly
altered the levels of Aβ40. Because Aβ40 is involved in long
term potentiation (Wu et al., 1995), we hypothesize that
truncated tau impedes synaptic activity via dysregulation of
Aβ40 pathway. This suggests that amyloid β changes arise
downstream of truncated tau pathology in the transgenic
animals.
Detailed evaluation of functional consequences of truncated-
tau on synaptic transmission, however, is beyond the scope of this
study. Here we focused solely on the structural synaptic damage
associated with the expression of truncated tau in the cortex
of transgenic rats. Whether the observed changes in synaptic
proteome have an immediate or gradual differential impact on
synaptic transmission, or whether the expression of tau damages
all or only a subset of synapses for a given neuron are important
question which deserve a further study. However, recent study
demonstrates that truncated tau (aa 1–369) is sufficient to
induce synaptic and dendritic loss and reduce the field excitatory
post-synaptic potential leading to the cognitive decline (Zhang
et al., 2014).
Finally, we cannot completely exclude the effect of tau
overexpression on the synaptic damage, however we can see
specific pattern of synaptic damage in the cortex of transgenic
rats. First of all, not all proteins are affected. Furthermore
microtubular network is mainly damaged in the presynaptic
compartment while neurofilaments are altered in postsynaptic
compartment. It is important to mention that overexpression
of truncated tau is similar in both compartments. Therefore we
suggest that dysregulation of synaptic markers are caused by tau
truncation rather than tau overexpression.
In conclusion, truncated tau protein displayed different
phospho-patterns in the pre- and postsynaptic compartments,
which was associated with selective damage of microtubular
network in the presynaptic compartment and deregulation
of neurofilaments in the post-synaptic density. Importantly,
although the truncated tau protein orchestrated the synaptic
deficits independently from Aβ42, it significantly regulated Aβ40.
The study opens new avenues for better understanding of synaptic
pathology in AD and related neurodegenerative diseases.
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